INT986

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1979
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 16
Total Number 17
Disease Relevance 8.57
Pain Relevance 3.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (GHRH) extracellular region (GHRH) cell-cell signaling (GHRH)
Anatomy Link Frequency
pancreatic islet 2
neurons 2
GHRH (Homo sapiens)
Pain Link Frequency Relevance Heat
Clonidine 9 100.00 Very High Very High Very High
Endogenous opioid 2 99.72 Very High Very High Very High
antagonist 22 99.00 Very High Very High Very High
Somatostatin 138 98.46 Very High Very High Very High
Pain 8 98.44 Very High Very High Very High
Pain threshold 5 98.40 Very High Very High Very High
narcan 1 97.72 Very High Very High Very High
tolerance 10 97.02 Very High Very High Very High
analgesia 1 92.84 High High
agonist 20 91.32 High High
Disease Link Frequency Relevance Heat
Propionic Acidemia 3 99.90 Very High Very High Very High
Galactorrhea 1 99.90 Very High Very High Very High
Obesity 39 99.84 Very High Very High Very High
Diabetes Mellitus 37 99.84 Very High Very High Very High
Acromegaly 7 99.84 Very High Very High Very High
Thyroid Disease 2 99.84 Very High Very High Very High
Appetite Loss 13 99.80 Very High Very High Very High
Hypoglycemia 164 99.24 Very High Very High Very High
Noonan Syndrome 10 98.84 Very High Very High Very High
Pain 13 98.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
She also had hyperprolactinaemia and decreased human growth hormone secretion.
Negative_regulation (decreased) of Localization (secretion) of growth hormone associated with galactorrhea
1) Confidence 0.58 Published 1993 Journal Eur. J. Pediatr. Section Abstract Doc Link 7687546 Disease Relevance 0.93 Pain Relevance 0.10
Two patients with propionic acidemia had decreased growth hormone secretion in response to provocative stimuli (intravenous L-arginine and oral levodopa or clonidine); the remaining subjects had sufficient growth hormone secretion.
Negative_regulation (decreased) of Localization (secretion) of growth hormone associated with propionic acidemia and clonidine
2) Confidence 0.58 Published 1994 Journal Biochem. Med. Metab. Biol. Section Abstract Doc Link 7993663 Disease Relevance 0.19 Pain Relevance 0.10
Elevation of dental pain threshold induced in man by physical exercise is not reversed by cyproheptadine-mediated suppression of growth hormone release.
Negative_regulation (suppression) of Localization (release) of growth hormone associated with pain threshold and narcan
3) Confidence 0.57 Published 1986 Journal Neurosci. Lett. Section Title Doc Link 3774237 Disease Relevance 0.45 Pain Relevance 0.65
Glucocorticoids may inhibit growth hormone release by enhancing beta-adrenergic responsiveness in hypothalamic somatostatin neurons.
Spec (may) Negative_regulation (inhibit) of Localization (release) of growth hormone in neurons associated with somatostatin
4) Confidence 0.51 Published 1993 Journal J. Clin. Endocrinol. Metab. Section Title Doc Link 8094392 Disease Relevance 0 Pain Relevance 0.15
Our results argue against the hypothesis of an enhanced SRIH tone as the cause of impaired GH secretion in obese patients, a primary defect in GHRH or GH release seems more likely.
Negative_regulation (defect) of Localization (release) of GHRH associated with obesity
5) Confidence 0.49 Published 1995 Journal Int. J. Obes. Relat. Metab. Disord. Section Abstract Doc Link 7719386 Disease Relevance 0.60 Pain Relevance 0.09
A physiological decrease in growth hormone (GH) and IGF-I secretion accompanies these changes.
Negative_regulation (decrease) of Localization (secretion) of growth hormone
6) Confidence 0.33 Published 1993 Journal Rev Clin Esp Section Abstract Doc Link 8497741 Disease Relevance 0.19 Pain Relevance 0
Suppression of clonidine-induced release of growth hormone by thyrotropin releasing hormone in humans.
Negative_regulation (Suppression) of Localization (release) of growth hormone associated with clonidine
7) Confidence 0.31 Published 1979 Journal J. Endocrinol. Invest. Section Title Doc Link 119798 Disease Relevance 0.09 Pain Relevance 0.38
In humans, corticoids suppress growth and growth hormone (GH) secretion elicited by a variety of stimuli, while in the rat they potentiate both in vivo and in vitro GH release.
Negative_regulation (suppress) of Localization (secretion) of growth hormone
8) Confidence 0.22 Published 1990 Journal Neuroendocrinology Section Abstract Doc Link 2106087 Disease Relevance 0.16 Pain Relevance 0.12
GHRH and GH release, locomotor suppression and appetite stimulation [26, 43–45].
Negative_regulation (suppression) of Localization (release) of GHRH associated with appetite loss
9) Confidence 0.18 Published 2010 Journal International Journal of Peptides Section Body Doc Link PMC2925380 Disease Relevance 0.10 Pain Relevance 0.07
Somatostatin and its analogue-prolonged release formulation, lanreotide (Somatuline PR), inhibit the secretion of growth hormone.
Negative_regulation (inhibit) of Localization (secretion) of growth hormone associated with somatostatin
10) Confidence 0.17 Published 1999 Journal Endocr. J. Section Abstract Doc Link 10426587 Disease Relevance 0.25 Pain Relevance 0.05
Defective growth hormone (GH) secretion and short-term treatment in Noonan syndrome.
Negative_regulation (Defective) of Localization (secretion) of growth hormone associated with noonan syndrome
11) Confidence 0.15 Published 1998 Journal Indian J Pediatr Section Title Doc Link 10773931 Disease Relevance 1.17 Pain Relevance 0.08
The beta-endorphin-induced secretion of growth hormone but not of prolactin is inhibited by an endogenous opioid antagonist.
Negative_regulation (inhibited) of Localization (secretion) of growth hormone associated with antagonist and endogenous opioid
12) Confidence 0.15 Published 1986 Journal Eur. J. Pharmacol. Section Title Doc Link 2946593 Disease Relevance 0 Pain Relevance 0.24
The obese showed impaired growth hormone release after both DAMME and insulin-induced hypoglycaemia compared to the lean subjects.
Negative_regulation (impaired) of Localization (release) of growth hormone associated with hypoglycemia and obesity
13) Confidence 0.12 Published 1987 Journal Horm. Metab. Res. Section Abstract Doc Link 3104184 Disease Relevance 0.92 Pain Relevance 0.34
Reduced glucose tolerance and hyperglycaemia that might be expected is limited with long-term therapy by the ability of octreotide to delay absorption of carbohydrate and to inhibit the secretion of growth hormone and glucagons.
Negative_regulation (inhibit) of Localization (secretion) of growth hormone associated with tolerance and impaired glucose tolerance
14) Confidence 0.06 Published 2005 Journal Crit Care Section Body Doc Link PMC1414034 Disease Relevance 1.42 Pain Relevance 0.27
Octreotide is clinically used to suppress excessive growth hormone secretion in acromegaly, to inhibit thyrotropin-secreting pituitary adenomas (thyrotrophinomas), and to treat flushing and diarrhoea associated with certain gastroenterological or pancreatic neuroendocrine tumours, especially carcinoid tumors and pancreatic islet cell tumors (insulinomas), which produce a variety of peptide hormones and biogenic amines [10-12].
Negative_regulation (suppress) of Localization (secretion) of growth hormone in pancreatic islet associated with carcinoid, acromegaly, islet cell adenoma, neuroendocrine cancer, diarrhoea, pituitary cancer, insulinoma and increased venous pressure under development
15) Confidence 0.04 Published 2005 Journal Crit Care Section Body Doc Link PMC1414034 Disease Relevance 1.04 Pain Relevance 0.20
Octreotide is, for instance, 45 times more potent in inhibiting growth hormone (GH) secretion and 11 times more potent in inhibiting glucagon secretion than native SST [10].


Negative_regulation (inhibiting) of Localization (secretion) of growth hormone associated with somatostatin
16) Confidence 0.03 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2845555 Disease Relevance 0.35 Pain Relevance 0.33
There is evidence that nutrient-induced secretion of the glucose-regulating incretin hormone, glucagon-like peptide-1 (GLP-1), is impaired in type 2 diabetes mellitus [4].
Negative_regulation (impaired) of Localization (secretion) of incretin hormone associated with diabetes mellitus
17) Confidence 0.01 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2997321 Disease Relevance 0.64 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox